BIOLASE, INC false 0000811240 --12-31 0000811240 2023-05-24 2023-05-24

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 24, 2023

 

 

BIOLASE, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36385   87-0442441

(State or other jurisdiction

of incorporation)

 

(Commission

File No.)

 

(IRS Employer

Identification No.)

27042 Towne Centre Drive, Suite 270

Lake Forest, California 92610

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (949) 361-1200

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   BIOL  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

 


Item 1.01.

Entry into a Material Definitive Agreement.

On May 24, 2023, BIOLASE, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as representative of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to sell to the Underwriters, in a firm commitment underwritten public offering, 175,000 units (each a “Unit” and collectively, the “Units”), with each Unit consisting of (A) one share of the Company’s Series H Convertible Redeemable Preferred Stock, par value $0.001 per share (the “Series H Convertible Preferred Stock”), and (B) one warrant (each, a “Warrant” and collectively, the “Warrants”) to purchase one-half of one (0.50) share of Series H Convertible Preferred Stock, at a price to the public of $26.00 per Unit, less underwriting discounts and commissions. The public offering price of $26.00 per Unit reflects the issuance of the Series H Convertible Preferred Stock with an original issue discount (“OID”) of 48%. The Company is also registering under the Registration Statement (as defined below) an additional 80,769 shares of Series H Convertible Preferred Stock (“PIK Dividend Shares”) that will be issued, if and when the Company’s Board of Directors declares such dividends, as paid in-kind dividends (“PIK dividends”) and the shares of Common Stock issuable upon conversion of the Series H Convertible Preferred Stock issued as PIK dividends (the “PIK Conversion Shares”).

The Units, the shares of Series H Convertible Preferred Stock, the Warrants, the PIK Dividend Shares, the PIK Conversion Shares as well as the shares of Series H Convertible Preferred Stock issuable upon exercise of the Warrants and the shares of the Company’s common stock, par value $0.001 per share (the Common Stock”), issuable upon conversion of the Series H Convertible Preferred Stock, are being offered and sold (the “Offering”) by the Company pursuant to an effective registration statement on Form S-1, as amended (File No. 333-271660) (the “Registration Statement”), which was initially filed with the Securities Exchange Commission (“SEC”) on May 4, 2023, as amended on May 18, 2023, May 22, 2023 and May 24, 2023, and declared effective by the SEC on May 24, 2023. A final prospectus relating to the Offering was filed with the SEC on May 25, 2023. The closing of the Offering contemplated by the Underwriting Agreement occurred on May 26, 2023.

The Underwriting Agreement contains customary representations, warranties and covenants by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. Lake Street Capital Markets, LLC and Maxim Group LLC acted as joint bookrunners for this Offering.

The foregoing description of the material terms of the Underwriting Agreement is qualified in its entirety by reference to the full text thereof, a copy of which is attached to this Current Report on Form 8-K as Exhibit 1.1 and is incorporated by reference herein.

The Warrants are being issued pursuant to the terms of that certain warrant agency agreement (the “Warrant Agency Agreement”) to be entered into by and among the Company, Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate Computershare Trust Company, N.A., a federally chartered trust company (together with Computershare, the “Warrant Agent”). A copy of the Warrant Agency Agreement and the form of Warrant are attached to this Current Report on Form 8-K as Exhibits 4.1 and 4.2, respectively, and are incorporated by reference herein.

Each Warrant has an exercise price of $13.00 per share, is exercisable for one-half of one (0.5) share of Series H Convertible Preferred Stock, is immediately exercisable and will expire two (2) years from the date of issuance.

There is no established trading market for the Series H Convertible Preferred Stock or the Warrants and we do not expect a market to develop. In addition, we do not intend to list the Series H Convertible Preferred Stock or the Warrants on The Nasdaq Capital Market or any other national securities exchange or any other nationally recognized trading system.

The gross proceeds to the Company from this Offering are expected to be approximately $4.5 million, assuming no exercise of the Warrants and before deducting underwriting discounts and commissions and Offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for working capital and for general corporate purposes.

 

Item 3.03.

Material Modification to Rights of Security Holders.

On May 25, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series H Convertible Redeemable Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware designating 370,000 shares of the Company’s authorized preferred stock as Series H Convertible Preferred Stock, with a liquidation preference of $50.00 per share plus any accrued and unpaid dividends, and further establishing the number of shares of Series H Convertible Preferred Stock, and to fix the designation, powers, preferences and rights of the shares of Series H Convertible Preferred Stock and the qualifications, limitations or restrictions thereof.

 

-2-


The Series H Convertible Preferred Stock will not have voting rights, except as required by Delaware law and other limited circumstances.

Dividends on the Series H Convertible Preferred Stock shall be paid in-kind (PIK dividends) in additional shares of Series H Convertible Preferred Stock based on the stated value of $50.00 per share at the dividend rate of 20.0% (the “Dividend Rate”). The PIK dividends will be a one-time payment payable to holders of the Series H Convertible Preferred Stock of record at the close of business on the one-year anniversary of the closing date of this offering (the “Original Issuance Date”) (the “Dividend Record Date”). PIK dividends on each share of Series H Convertible Preferred Stock shall be paid three (3) business days after the Dividend Record Date in additional fully paid and nonassessable, registered shares of Series H Convertible Preferred Stock in a number equal to the quotient obtained by dividing (A) the product obtained by multiplying (i) the Dividend Rate and (ii) the stated value of $50.00 per share, by (B) the public offering price per Unit (equal to $26.00).

The Series H Convertible Preferred Stock has a term of two (2) years and is convertible at the option of the holder at any time into shares of our common stock at a fixed conversion price of $0.1398, which fixed conversion price is based on the closing price of our common stock on May 23, 2023, and is subject to adjustment.

If any shares of Series H Convertible Preferred Stock are outstanding at the end of the two (2) year term, then the Company is required to promptly redeem all of the outstanding shares of Series H Convertible Preferred Stock on a pro rata basis in cash at a price per share equal to the sum of (i) 100% of the Stated Value plus (ii) all other amounts due in respect of the Series H Preferred Stock.

The terms of the Series H Convertible Preferred Stock are more fully described in the Certificate of Designation, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference herein.

 

Item 5.03.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

The disclosures in Item 3.03 of this Current Report on Form 8-K are incorporated herein by reference.

On May 24, 2023, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware to establish the powers, preferences and rights of the shares of the Series H Convertible Preferred Stock and the qualifications, limitations or restrictions thereof.

The terms of the Certificate of Designation are more fully described in the Certificate of Designation, a copy of which is included as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference herein.

 

Item 8.01.

Other Events.

On May 24, 2023, the Company issued a press release announcing the pricing of the Offering. On May 26, 2023, the Company issued a press release announcing the closing of the Offering. Copies of each of these press releases are attached hereto as Exhibits 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.

 

-3-


Item 9.01.

Financial Statements and Exhibits.

(d)    Exhibits

The following exhibits are filed as a part of this Current Report on Form 8-K:

 

Exhibit

Number

  

Description

  1.1    Underwriting Agreement, dated May 24, 2023, by and between BIOLASE, Inc. and Lake Street Capital Markets, LLC, as representative of the several underwriters named therein
  3.1    Certificate of Designation of Preferences, Rights and Limitations of Series H Convertible Redeemable Preferred Stock, dated May 25, 2023
  4.1    Warrant Agency Agreement, dated May 26, 2023, by and between BIOLASE, Inc., Computershare Inc., a Delaware corporation, and its affiliate, Computershare Trust Company, N.A., a federal trust company. 
  4.2    Form of Warrant to Purchase Shares of Series H Convertible Preferred Stock
99.1    Press Release of BIOLASE, Inc., dated May 24, 2023
99.2    Press Release of BIOLASE, Inc., dated May 26, 2023
104    Cover Page Interactive Data File (formatted in Inline XBRL)

 

-4-


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    BIOLASE, INC.
Date: May 26, 2023     By:  

/s/ John R. Beaver

    Name:   John R. Beaver
    Title:   Chief Executive Officer

 

-5-